Decreased Cerebral Glucose Utilization in Myotonic Dystrophy
Affiliations
To test the hypothesis that cerebral metabolism is altered in myotonic dystrophy (MyD), we investigated cerebral glucose kinetics and utilization in 11 adult patients with MyD and 14 healthy controls, using 18F-labeled 2-fluoro-2-deoxy-D-glucose (FDG) and dynamic positron emission tomography. Estimation of rate constants in MyD revealed a reduction of FDG delivery to the brain. Cortical glucose utilization rate was reduced by about 20% in MyD. These findings may be related to the presence of neurologic impairment in MyD and prompt further investigations on the metabolic and clinical features of brain dysfunction in this disease.
Wu Y, Wei Q, Lin J, Shang H, Ou R Front Cell Neurosci. 2024; 18:1369332.
PMID: 38638300 PMC: 11024338. DOI: 10.3389/fncel.2024.1369332.
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
Liu J, Guo Z, Yan X, Yang Y, Huang S Front Aging Neurosci. 2021; 13:755392.
PMID: 34867280 PMC: 8634727. DOI: 10.3389/fnagi.2021.755392.
Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.
Nieuwenhuis S, Okkersen K, Widomska J, Blom P, t Hoen P, van Engelen B Front Neurol. 2019; 10:1229.
PMID: 31849810 PMC: 6901991. DOI: 10.3389/fneur.2019.01229.
Advances in imaging of brain abnormalities in neuromuscular disease.
Angelini C, Pinzan E Ther Adv Neurol Disord. 2019; 12:1756286419845567.
PMID: 31105770 PMC: 6503605. DOI: 10.1177/1756286419845567.
Current Progress in CNS Imaging of Myotonic Dystrophy.
Minnerop M, Gliem C, Kornblum C Front Neurol. 2018; 9:646.
PMID: 30186217 PMC: 6110944. DOI: 10.3389/fneur.2018.00646.